Huma Therapeutics has completed its latest funding round with raising financing of approximately $130m (£91m).
The investment will be used by the UK health tech firm to scale its modular platform and support pharmaceutical and research industries to run decentraliased clinical trials.
It intends to expand the platform into the US, Asia and the Middle East.
The platform combines predictive algorithms, digital biomarkers and real-world data to advance proactive care and research.
A further commitment of $70m that can be exercised at a later date has also been agreed as part of the Series C funding round and takes the total financing raised to more than $200m.
Dan Vahdat, founder and CEO of Huma, said: “This is a pivotal moment in Huma’s development. We have exceptional partners and strategic investors who will support us in our mission to help people worldwide live longer and fuller lives.
“We’re already demonstrating how ‘hospital at home’ can transform healthcare, and how decentralized clinical trials can advance research in ways that weren’t imaginable even one year ago.
“Now we want to accelerate the pace of change and continue to innovate for better care and research worldwide.’’
Leaps by Bayer and Hitachi Ventures led the latest funding round, which saw new strategic and financial investors become shareholders.
These include Samsung Next, Sony Innovation Fund by IGV, Unilever Ventures and HAT Technology & Innovation Fund by HAT, as well as former SoftBank president Nikesh Arora and Allianz chairman Michael Diekmann.
